Consider interruption or discontinuation of treatment if there is evidence of worsening liver disease. Avoid use in antiretroviral-experienced patients w/ HIV-1 harbouring K65R mutation. Discontinue treatment in patients w/ estimated CrCl that declines <30 mL/min during treatment. Residual risk of sexual transmission. Increased wt, & blood lipid & glucose levels. Mitochondrial dysfunction following exposure
in utero. Haematological (anaemia, neutropenia), metabolic (hyperlactatemia, hyperlipasemia) & neurological (hypertonia, convulsion, abnormal behaviour) disorders. Cytomegalovirus retinitis, generalized &/or focal mycobacterial infections, &
Pneumocystis jirovecii pneumonia; Graves' disease. May continue to develop opportunistic infections & other complications of HIV infection. Cases of osteonecrosis. Potential risk of nephrotoxicity resulting from chronic exposure. Patients co-infected w/ HIV & HBV or HCV; w/ pre-existing liver dysfunction including chronic active hepatitis. Closely monitor w/ both clinical & lab follow-up for at least several mth after discontinuation in patients co-infected w/ HIV & HBV. Monitor blood lipids & glucose. Concomitant use w/ 3rd nucleoside analogue. Not recommended in concomitant use w/ anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarb, phenytoin), antimycobacterials (eg, rifampicin, rifabutin, rifapentine), boceprevir, telaprevir, St. John's wort, HIV PIs other than atazanavir, lopinavir, darunavir; medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil. May affect ability to drive & use machines. Liver disease. ESRD (estimated CrCl <15 mL/min) on chronic haemodialysis. Pregnancy. Not to be used during lactation. Childn <12 yr weighing <35 kg.
Sign Out
